Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins

Abstract excerpt

Despite high initial responses after treatment with anti-CD19 chimeric antigen receptor (CAR) T cells in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), 40–50% of patients relapse within 24 months 1 , 2 . In solid tumors, PD-1/-L1 (programmed death (ligand) 1) blockade enhances, i.e., Her2-specific CAR function 3 . Although BCP-ALL and bone marrow T cells express PD-L1/PD-1 4 , 5 , clinical...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to Nanowire Synthesis and Applications